Sword Bio Appoints Kara Harrison as Vice President, Quality Assurance
Sword Bio (“Sword”), a contract research organization that supports biotech and pharmaceutical companies with their bioanalytical needs for research, pre-clinical and clinical trials, announces the appointment of Kara Harrison as VP of Quality Assurance.
Kara joins Sword with a proven record of leading and scaling quality management programs and initiatives. Most recently, she was VP, of Global Quality for BioAgilytix Labs. In this position Kara led a globally dispersed team of quality professionals, working to standardize procedures and quality systems across distinct sites, delineating best practices, and collaborating with clients and colleagues at all levels to enhance quality.
Kara puts an emphasis on expanding business capabilities and driving operational success in the contract research space, providing quality oversight, implementation, guidance, and consultation regarding Quality Assurance and Regulatory Compliance (QA/RC) in pharmaceutical, device, and biopharma Good Clinical Practices (GCP), Good Laboratory and Clinical Laboratory Practices (GLP/GcLP).
“We are so delighted to have Kara join Sword Bio as our VP of Quality Assurance,” said David Dingott, CEO. “Our customers expect the highest level of quality in everything we do. Kara has both leadership skills and industry-leading expertise in scaling CRO quality systems and compliance. I can think of no better way to demonstrate our commitment to quality than having Kara lead our quality efforts.”
“I am excited to join the team at Sword and be part of such a talented team.” Said Kara. “We are focused on providing our customers and the end users of their therapies with the best science and data quality possible. I look forward to supporting our partners in their development journey.”
Sword Bio is a leading bioanalytical CRO supporting biotech and pharmaceutical companies with research-grade assays, GLP pre-clinical and clinical assay development, validation, and sample analysis. We assist clients with PK, biomarkers, and various types of immunogenicity assays for a variety of therapeutic and disease states.
Sword’s team is comprised of industry-experienced science and QA professionals ensuring the highest levels of science, data integrity, and regulatory compliance through all phases of clinical development.
Sword has built an innovative excess capacity model that offers its partners no lead times, transparency, communication, and white-glove service so that our clients can quickly achieve their goals.
For more information, visit www.swordbio.com.